3.24
+0.04000001(+1.25%)
Currency In USD
| Previous Close | 3.2 |
| Open | 3.2 |
| Day High | 3.28 |
| Day Low | 3.15 |
| 52-Week High | 4.98 |
| 52-Week Low | 1.15 |
| Volume | 638,687 |
| Average Volume | 2.79M |
| Market Cap | 156.52M |
| PE | -1.46 |
| EPS | -2.22 |
| Moving Average 50 Days | 3.39 |
| Moving Average 200 Days | 2.43 |
| Change | 0.04 |
If you invested $1000 in Cassava Sciences, Inc. (SAVA) 10 years ago, it would be worth $1,723.4 as of December 10, 2025 at a share price of $3.24. Whereas If you bought $1000 worth of Cassava Sciences, Inc. (SAVA) shares 5 years ago, it would be worth $2,945.45 as of December 10, 2025 at a share price of $3.24.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
GlobeNewswire Inc.
Oct 22, 2025 12:00 PM GMT
AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tub
Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Aug 25, 2025 12:00 PM GMT
AUSTIN, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, such as Tu
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
GlobeNewswire Inc.
Aug 07, 2025 11:30 AM GMT
Joseph Hulihan, MD, MSHP, brings substantial clinical development experience advancing novel therapies for TSC-related epilepsy and other neurological disordersClinical study for simufilam in TSC-related epilepsy expected to begin in H1 2026 AUSTIN,